Loading…
← CockpitCompetitor Analysis › 688046.SS GemPharmatech Co., Ltd. Class AOpen in the cockpit ↗

GemPharmatech Co., Ltd. Class A688046.SSCompetitor analysis, valuation and peers

China · CNY·Health Care›Biotechnology

Chinese laboratory-animal model provider, breeding genetically engineered mice for biomedical research and drug development.

≈ A Chinese Jackson Laboratory / Charles River mouse-model businessMomentum leader 90
Mkt cap
$1.78B
US dollars, full cap
Free float
41%
of shares outstanding
$/day
$36.3M
20-day average traded
Fwd P/E
51.9×
forward earnings
ROIC−WACC
+2.5 pp
WACC 12.6%
Hurdle
+8 pp
Req g minus delivered
Next earnings
159 days
26 Apr 2027
Close · CNYCN¥29.91
1D-7.1%
1W-11.8%
1M-1.1%
3M-27.0%
6M+39.0%
YTD+94.7%
1Y+65.7%
ATR %9.0%
52w lowhigh31.2% off high

What GemPharmatech does

Chinese laboratory-animal model provider, breeding genetically engineered mice for biomedical research and drug development.

Sells live mice from a stock catalogue of its genetically engineered strains, a repeat revenue source because labs reorder animals for experiments, with custom model creation and testing services as add-ons. Sales go mainly to pharma, biotech and research institutes in China, so R&D budgets decide demand.

In one line: A Chinese Jackson Laboratory / Charles River mouse-model business.

Products and services

  • Genetically engineered mouse models
  • Model breeding/production services
  • Preclinical pharmacology services

Customers

  • Pharma/biotech R&D labs
  • Academic research institutes

Where it sits in the supply chain

  • Health Care
  • Pharma services
  • Laboratory animal models

What could go right

  • China biotech R&D spending growth
  • Preclinical outsourcing trend

What could go wrong

  • Biotech funding cyclicality
  • Competition on model pricing

Moat: narrow (scale, installed base, process know-how). Large, standardized mouse-model catalog and breeding scale that is slow for customers to replicate in-house.

Headquarters: Nanjing, China · Employees: 1,590

Named competitors

GemPharmatech at a glance

Size GemPharmatech (688046.SS) is a China Health Care company (Biotechnology) with a market value of $1.78B, the 1299th largest of 4,790 China companies the cockpit tracks. Shares closed at CN¥29.91 on 18 Nov 2026.

Performance Over six months the shares gained 39.0%, against -2.8% for the median peer and -20.0% for the China market (cap-weighted) — 6th highest of 20 in its peer set.

Growth Revenue grew 25.0% over the last twelve months (peer median +10.8%); the operating margin is 22.3% (peer median -46.1%).

Valuation It trades at 51.9× forward earnings against a peer median of 22.6× (3rd most expensive of 8).

Price implies For today's price to make sense, revenue must grow about 33% a year for seven years (Req g). Recent delivered growth is +25%, so the hurdle is +8 pp: the price needs faster growth than the company has been delivering — of companies that just grew 25–50% a year, 93.8% slowed down over the next four years.

Capital Return on invested capital runs 2.5 points above its cost of capital (12.6% WACC).

Next results Next results expected around 26 Apr 2027 (exchange calendar; dates can move).

Relative performance

10015020021 May 202621 Aug 202618 Nov 2026688046.SS 141Peer median 95
Six months, rebased to 100: GemPharmatech against the median of its 20 peers (local-currency closes).

GemPharmatech financials

Reported figures in CNY; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
RevenueCN¥941MCN¥792MCN¥687MCN¥622MCN¥516M
Revenue growth—+15%+10%+20%—
Gross profitCN¥684MCN¥502MCN¥421MCN¥418MCN¥367M
EBITDAn/aCN¥243MCN¥188MCN¥173MCN¥147M
Net incomeCN¥203MCN¥143MCN¥110MCN¥159MCN¥165M
Free cash flowCN¥280MCN¥139M-CN¥2,830-CN¥78.4M-CN¥74.1M
Capital expenditureCN¥71.1MCN¥105MCN¥114MCN¥206MCN¥190M
Total debtCN¥209MCN¥291MCN¥132MCN¥122MCN¥17.9M

Quarterly statements and history in the cockpit →

GemPharmatech competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

0%+100%+200%+300%0%+50%ZBIORXRXSTOKCOAGVERA300601145020TRAXSEPNREPLMRVIALVO6882226949688046.SS6-month return →1-month return →
Up and to the right = strong over both horizons. GemPharmatech is the large dot.

Fundamentals: revenue growth against valuation

-20%0%+20%+40%+60%0×50×100×300601145020BCRX600226ANIPALVO688222688046.SSRevenue growth (TTM) →Forward P/E →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. GemPharmatech is the large dot.

Capital: growth delivered against growth the price implies

0%+50%+100%0%50%100%300601145020BCRXANIP688222688046.SSGrowth delivered (Del g) →Growth the price implies (Req g, 7 yrs) →
Above the diagonal = the price needs more growth than the company has been delivering; below = the price already allows for a slowdown. GemPharmatech is the large dot.

GemPharmatech competitors and peer comparison

Head to head with its named competitors (688046.SS vs CRL)
CompanyMarket cap6M returnRevenue growthOp. marginForward P/EReq g
GemPharmatech 688046.SS$1.78B+39%+25%22%51.9×33.0%
Charles River Laboratories CRL$16.0B+114%-1%15%26.2×25.6%

How GemPharmatech compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

GemPharmatech against its 20 peers (data as of 18 Nov 2026)
Measure688046.SSPeer medianRank in peer set
1-month return-1.1%-1.6%10th highest of 20
6-month return+39.0%-2.8%6th highest of 20
Distance from 52-week high-31.2%-34.3%9th highest of 21
Revenue growth (TTM)+25.0%+10.8%7th highest of 16
Operating margin22.3%-46.1%4th highest of 17
Forward P/E51.9×22.6×3rd most expensive of 8
Growth the price implies (Req g, 7 yrs)33.0%-7.6%2nd most demanding of 6
Growth delivered (Del g)+24.8%+16.8%3rd highest of 6
Hurdle (Req g minus delivered)+8.1 pp-27.1 pp3rd most demanding of 6
ROIC minus cost of capital+2.5 pp-6.3 pp4th highest of 11

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginForward P/EReq gDelivered g
GemPharmatech 688046.SSChina$1.78B+39%+25%22%51.9×33.0%+24.8%
Zenas BioPharma ZBIOUnited States$1.79B+35%-27%-2,748%n/an/an/a
Recursion Pharmaceuticals RXRXUnited States$1.76B-5%+56%-725%n/an/an/a
Lycia Therapeutics LYCAUnited States$1.81Bn/a-55%-593%n/an/an/a
Stoke Therapeutics STOKUnited States$1.75B-12%-86%-913%n/an/an/a
Hemab Therapeutics COAGUnited States$1.83B+48%n/an/an/an/an/a
Vera Therapeutics VERAUnited States$1.85B-26%n/a-4,160%n/an/an/a
Shenzhen Kangtai Biological Products 300601.SZChina$1.86B-20%-9%6%105.5×22.7%+3.4%
Hugel 145020.KSSouth Korea$1.69B-30%+17%38%18.1×-12.1%+15.0%
First Tracks Biotherapeutics TRAXUnited States$1.87B+175%n/an/an/an/an/a
Septerna SEPNUnited States$1.88B+41%+337%-76%n/an/an/a
Replimune REPLUnited States$1.88B+321%n/an/an/an/an/a
BioCryst Pharmaceuticals BCRXUnited States$1.88B-16%+60%42%11.1×-11.0%+117.9%
Sinocelltech 688520.SSChina$1.90B-35%-40%-75%n/an/an/a
Maravai Lifesciences MRVIUnited States$1.92B+101%+11%-17%n/an/an/a
Trevi Therapeutics TRVIUnited States$1.93B-3%n/an/an/an/an/a
Zhejiang Hengtong 600226.SSChina$1.64B-31%+71%0%27.6×n/an/a
ANI Pharmaceuticals ANIPUnited States$1.62B-13%+26%15%7.5×-7.6%+33.5%
Alvotech ALVOUnited States$1.62B+38%-14%12%22.6×n/an/a
Hitgen 688222.SSChina$1.62B-3%+42%27%73.2×33.2%+16.8%
PELL Bio-Med Technology 6949.TWTaiwan$1.62B+28%+8%-1,463%n/an/an/a

Questions

Who are GemPharmatech's main competitors?
Named competitors: Charles River Laboratories (CRL), Cyagen Biosciences (private or unlisted). The cockpit's measured peer set (industry) also includes Zenas BioPharma (ZBIO), Recursion Pharmaceuticals (RXRX), Lycia Therapeutics (LYCA), Stoke Therapeutics (STOK), Hemab Therapeutics (COAG), Vera Therapeutics (VERA).
Is GemPharmatech expensive compared with its peers?
On forward p/e it trades at 51.9× against a peer median of 22.6×, 3rd most expensive of 8 in its peer set. For today's price to make sense, revenue must grow about 33% a year for seven years (Req g). Recent delivered growth is +25%, so the hurdle is +8 pp: the price needs faster growth than the company has been delivering — of companies that just grew 25–50% a year, 93.8% slowed down over the next four years.
How has GemPharmatech stock performed?
Over six months to 18 Nov 2026 the shares returned +39.0% against -2.8% for the median peer; over one year +65.7%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.